XML 44 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Mar. 31, 2023
USD ($)
Compounds
shares
Mar. 31, 2022
USD ($)
shares
Description Of Business And Summary Of Significant Accounting Policies [Line Items]    
Cash and cash equivalents $ 15,301,000 $ 28,675,000
Restricted cash 143,000 143,000
Accumulated deficit (324,998,000) (307,739,000)
Cash flow from operations $ 12,408,000 $ 8,453,000
Issuance of common stock | shares 8,716,906 8,710,627
Proceeds from sale of common stock shares $ 0 $ 251,000
Restricted cash $ 100,000 100,000
Estimated useful life of the fixed assets The estimated useful lives of the fixed assets range between one and seven years.  
Impairment of long-lived assets $ 0 0
Acquired in-process research and development accrued expenses 2,000,000 0
Dilutive effect $ 0 $ 0
Common stock equivalents excluded from computing diluted net loss per share | shares 1,600,000 1,200,000
Maximum [Member]    
Description Of Business And Summary Of Significant Accounting Policies [Line Items]    
Maturity of highly liquid investment 3 months  
Useful life of fixed assets, range 7 years  
Minimum [Member]    
Description Of Business And Summary Of Significant Accounting Policies [Line Items]    
Useful life of fixed assets, range 1 year  
At-The-Market Facility [Member]    
Description Of Business And Summary Of Significant Accounting Policies [Line Items]    
Issuance of common stock | shares 0  
Metacrine, Inc. [Member] | Metacrine's FXR Program [Member]    
Description Of Business And Summary Of Significant Accounting Policies [Line Items]    
Number of clinically tested compounds | Compounds 2  
Number of discovery or preclinical compounds | Compounds 2,000  
Asset Acquisition, Price of Acquisition, Expected $ 4,000,000.0  
Upfront payment paid 2,000,000.0  
Acquired in-process research and development accrued expenses $ 2,000,000.0